Clinical Trial Update: A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase II study of RC48-ADC in HER2-positive metastatic or unresectable urothelial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Urothelial Carcinoma, Advanced Cancer | Phase 2 | Status: COMPLETED